MYO5C

Across TCGA pan-cancer cohorts, MYO5C mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYO5C data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYO5C mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYO5C expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where MYO5C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.855	0.470	.008	16	view →
HNSC	DFS	Quartile	III,IV	0.869	1.000	.020	11	view →
CCRCC	OS	Median	III,IV	0.829	0.570	.027	4	view →
LUAD	OS	Median	II,III,IV	0.468	0.778	.012	4	view →
LSCC	OS	Tertile	All	1.000	0.678	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYO5C–PDAC (DFS)

Open the PDAC breakdown →